Comparative Effectiveness and Safety of Doac Versus Warfarin Among Obese With Atrial Fibrillation

Proulx, Laurie-Anne Boivin; Potter, Brian J.; Perreault, Sylvie

doi:10.1016/s0735-1097(22)01043-9

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An ambulatory assessment of anti-Xa level for obese adults and a team-based evaluation involving hematologists and, additionally, drug-level monitoring for underweight patients have been proposed as possible solutions [ 229 ]. Nevertheless, DOACs seem to be more effective and safer than OACs among all BMI patients [ 230 ].…”

Section: Discussionmentioning

confidence: 99%

Management of Patients Treated with Direct Oral Anticoagulants in Clinical Practice and Challenging Scenarios

Lucà,

Oliva,

Abrignani

et al. 2023

JCM

View full text Add to dashboard Cite

It is well established that direct oral anticoagulants (DOACs) are the cornerstone of anticoagulant strategy in atrial fibrillation (AF) and venous thromboembolism (VTE) and should be preferred over vitamin K antagonists (VKAs) since they are superior or non-inferior to VKAs in reducing thromboembolic risk and are associated with a lower risk of intracranial hemorrhage (IH). In addition, many factors, such as fewer pharmacokinetic interactions and less need for monitoring, contribute to the favor of this therapeutic strategy. Although DOACs represent a more suitable option, several issues should be considered in clinical practice, including drug–drug interactions (DDIs), switching to other antithrombotic therapies, preprocedural and postprocedural periods, and the use in patients with chronic renal and liver failure and in those with cancer. Furthermore, adherence to DOACs appears to remain suboptimal. This narrative review aims to provide a practical guide for DOAC prescription and address challenging scenarios.

show abstract

Section: Discussionmentioning

confidence: 99%